SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Journal of Psychopharmacology
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Montgomery, S.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Montgomery, S.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Serotonin, sertraline and depression

Stuart Montgomery

Department of Psychiatry, St Mary's Hospital Medical School, London, UK

Sertraline is a highly selective serotonin re-uptake inhibitor (SSRI) whose efficacy in depression has been established in a number of large placebo-controlled studies in patients with moderate to severe major depressive episodes (DSM-III). This antidepressant efficacy appears to be significantly more effective than placebo and imipramine and at least of the same order as that of the reference tricyclic antidepressants (TCAs) amitriptyline, clomipramine and dothiepin. More recently, two double-blind parallel group studies have demonstrated comparable efficacy to another SSRI, fluoxetine. Sertraline has demonstrated efficacy in the long-term maintenance and prophylaxis of depression and is one of the few SSRIs currently indicated for the prevention of relapse and recurrence of depression. Fixed dose studies have confirmed the efficacy and optimal tolerability of the minimum 50 mg dose. The efficacy of sertraline, demonstrated across a broad spectrum of depression, and its consistently improved tolerability and safety profile over the TCAs, confirm its potential as a first- line treatment for acute and recurrent episodes of depression.

Key Words: 5-HT re-uptake inhibitors • SSRI • sertraline • depression • prevention • major depressive disorder • review

Journal of Psychopharmacology, Vol. 9, No. 2 suppl, 179-184 (1995)
DOI: 10.1177/0269881195009002021
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?




Advertisement